688 Transcriptome analyses in patients with myeloid malignances treated with the IRAK4 inhibitor emavusertib

Documenti analoghi

• 688 Transcriptome analyses in patients with myeloid malignances treated with the IRAK4 inhibitor emavusertib
  di: Daniel J DeAngelo, et al.
  Pubblicazione: (2023-11-01)
• FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
  di: Katja Seipel, et al.
  Pubblicazione: (2024-03-01)
• Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer
  di: Guillermo Garcia-Manero, et al.
  Pubblicazione: (2024-02-01)
• P1298: THE IRAK-4 INHIBITOR EMAVUSERTIB (CA-4948) FOR THE TREATMENT OF PRIMARY CNS LYMPHOMA
  di: C. Von Roemeling, et al.
  Pubblicazione: (2022-06-01)
• P473: DEVELOPMENT OF POTENTIAL BIOMARKERS FOR IRAK4 INHIBITOR EMAVUSERTIB IN HUMAN ACUTE MYELOID LEUKEMIA
  di: A. Ugolkov, et al.
  Pubblicazione: (2022-06-01)